Farxiga© (dapagliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Dapagliflozin was recently approved for oral use as an adjunct to diet and exercise in the treatment of type 2 diabetes mellitus.
- There is evidence that dapagliflozin improves glycemic control in patients with type 2 diabetes mellitus whose diabetes is not controlled with metformin monotherapy.
- There is evidence that dapagliflozin and glipizide are equally effective when used as adjuvant therapy in patients with type 2 diabetes mellitus whose diabetes is not controlled with metformin monotherapy.
- The long term safety and effectiveness of dapagliflozin has not been assessed.
- Dapagliflozin has not been compared to other SGLT2 inhibitors.
- Only a few studies have compared dapagliflozin’s effectiveness to other classes of antidiabetics.
Adapted from a poster presentation by former Mercer University College of Pharmacy student Andy Tran. Click the following image for more information: